ライフサイエンスコーパス: pregabalin

1 etic-neuralgia patient abruptly discontinued pregabalin.

2 randomly assigned: 117 to placebo and 116 to pregabalin.

3 ain processing may respond to agents such as pregabalin.

4 te to precursors for GABA analogues, such as pregabalin.

5 cium-independent) dye release are reduced by pregabalin.

6 However, pregabalin 1 was active in the DBA/2 model after oral (a

7 0 mg/day of pregabalin (-9.2), 600 mg/day of pregabalin (-10.3), and lorazepam (-12.0) were significa

8 y disorder were randomly assigned to receive pregabalin (150 mg/day or 600 mg/day), lorazepam (6 mg/d

9 received daily treatment, 182 with 300 mg of pregabalin, 178 with 0.25 mg of pramipexole, 180 with 0.

10 point compared with placebo (-8.4 +/- 0.8): pregabalin, 300 mg (-12.2 +/- 0.8, P<.001), 450 mg (-11.

11 were randomized to 4 weeks of treatment with pregabalin, 300 mg/d (n = 91), 450 mg/d (n = 90), or 600

12 tine (nine of 14 studies); 7.7 (6.5-9.4) for pregabalin; 7.2 (5.9-9.21) for gabapentin, including gab

13 ven placebo (73%, N=50 of 69), 600 mg/day of pregabalin (71%, N=50 of 70), or 150 mg/day or pregabali

14 le score in the patients given 150 mg/day of pregabalin (-9.2), 600 mg/day of pregabalin (-10.3), and

15 egabalin (71%, N=50 of 70), or 150 mg/day or pregabalin (90%, N=62 of 69).

16 y adds to our understanding of the action of pregabalin, a drug used for treatment of partial seizure

17 igned to evaluate the efficacy and safety of pregabalin, a novel alpha(2)-delta ligand, for treatment

18 -5-phosphonopentanoic acid], suggesting that pregabalin action depends on NMDA receptor activation.

19 The central acting gabapentoid pregabalin affords a modest 12% pain reduction in patien

20 reating fibromyalgia, compared with placebo, pregabalin alone is associated with a small increase in

21 potent neuropathic analgesics gabapentin and pregabalin (alpha2delta-1 and alpha2delta-2), were also

22 Pregabalin, an alpha(2)delta-1/-2 ligand, and an alpha(2

23 A series of pregabalin analogues were prepared and evaluated for the

24 nderwent randomization, of whom 108 received pregabalin and 101 received placebo; after randomization

25 Pregabalin and alprazolam produced a significantly great

26 peripheral edema and burning sensation with pregabalin and capsaicin.

27 cing pain, and newly developed ones, such as pregabalin and duloxetine, while specifically marketed f

28 he most frequent adverse events reported for pregabalin and lorazepam were somnolence and dizziness.

29 he primary analyses involved a comparison of pregabalin and placebo over a period of 12 weeks with us

30 Doses of pregabalin and placebo were increased over 4 weeks.

31 d a comparison of rates of augmentation with pregabalin and pramipexole over a period of 40 or 52 wee

32 of the alpha-2-delta ligands (gabapentin and pregabalin) and the norepinephrine/serotonin reuptake in

33 serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin; a weak recommendation for us

34 us adverse events reported by patients given pregabalin, and no withdrawal syndrome was associated wi

35 vior, and could be rescued by the analgesic, pregabalin, and the libido-enhancing drugs, apomorphine

36 Acute pregabalin application reversibly dilated pressurized ar

37 ralgia compared with placebo, gabapentin and pregabalin are associated with a modest increase in the

38 tine and milnacipran--and the anticonvulsant pregabalin are encouraging.

39 in that all four manufacturing steps to make pregabalin are performed in water.

40 Gabapentin and pregabalin are structurally related compounds with recog

41 In the pregabalin arm, 45 patients (38.8%) achieved the primary

42 (P = .009 and P = .007, comparing respective pregabalin arms to the placebo arm).

43 cities were significantly more common in the pregabalin arms, being more evident with the higher dose

44 get 75 mg twice daily and 150 mg twice daily pregabalin arms, respectively (P = .009 and P = .007, co

45 ovides support and a mechanism of action for pregabalin as a possible effective therapy in the treatm

46 n in patients with RLS who were treated with pregabalin as compared with placebo and pramipexole.

47 Pregabalin at 300 and 450 mg/day was associated with sig

48 Pregabalin at 450 mg/day improved several domains of hea

49 Pregabalin at 450 mg/day significantly reduced the avera

50 Pregabalin at 450 mg/day was efficacious for the treatme

51 nts were randomly assigned to receive either pregabalin at a dose of 150 mg per day that was adjusted

52 signed to receive 52 weeks of treatment with pregabalin at a dose of 300 mg per day or pramipexole at

53 -delta Type 1 substantially reduces specific pregabalin binding in CNS regions that are known to pref

54 In mutant mice, pregabalin binding was robust throughout regions where t

55 In vitro studies have shown that pregabalin binds with high affinity to the alpha(2)-delt

56 three-step synthesis of the medicinal agent pregabalin (commercialized by Pfizer under the trade nam

57 the basis of preliminary promising data that pregabalin decreased hot flashes.

58 Pregabalin decreases hot flashes and is reasonably well

59 Treatment with pregabalin did not significantly reduce the intensity of

60 In short-term treatment, pregabalin does not appear to have the withdrawal sympto

61 However, the mechanisms by which pregabalin exerts its therapeutic effects are not yet co

62 Pregabalin exhibits robust activity in preclinical assay

63 Prolonged (24-hour) pregabalin exposure did not alter total alpha(2)delta-1

64 l of 227 adverse events were reported in the pregabalin group and 124 in the placebo group.

65 sted leg-pain intensity score was 3.4 in the pregabalin group and 3.0 in the placebo group (adjusted

66 sted leg-pain intensity score was 3.7 in the pregabalin group and 3.1 in the placebo group (adjusted

67 Dizziness was more common in the pregabalin group than in the placebo group.

68 verse events was significantly higher in the pregabalin group than in the placebo group.

69 Of the 5 treatment groups, the 300-mg pregabalin group was the only medication group that diff

70 cebo; after randomization, 2 patients in the pregabalin group were determined to be ineligible and we

71 observation-carried-forward end point, the 3 pregabalin groups and the alprazolam group had significa

72 ntly (P<.02) improved by the 300- and 600-mg pregabalin groups, but not by the 450-mg pregabalin (wee

73 Zonisamide and pregabalin have recently obtained licences as adjuvant t

74 The role of pregabalin in CIBP with a clinical neuropathic pain comp

75 um channels is the major binding protein for pregabalin in CNS.

76 Our findings do not support the role of pregabalin in patients with CIBP receiving radiotherapy.

77 The aim of this study was to examine pregabalin in patients with CIBP receiving radiotherapy.

78 d, double-blind, placebo-controlled trial of pregabalin in patients with sciatica.

79 atically reduces alpha(2)-delta 1 binding to pregabalin in vitro.

80 Acute systemic administration of pregabalin in vivo also selectively prevented the migrat

81 ral nervous system (CNS) binding protein for pregabalin in vivo, a mutant mouse with an arginine-to-a

82 ) mice, the acute systemic administration of pregabalin increased the threshold for SD initiation in

83 nstriction ("myogenic tone"), and attenuated pregabalin-induced vasodilation.

84 At the cellular level, pregabalin inhibited glutamatergic synaptic transmission

85 Pregabalin inhibits release of excess excitatory neurotr

86 Pregabalin is a synthetic amino acid compound effective

87 These results indicate that pregabalin is an effective, rapidly acting, and safe tre

88 the intraocular pressure-lowering effect of pregabalin is dependent on the Cacna2d1 haplotype.

89 Pregabalin is effective in the treatment of some types o

90 The effect of pregabalin is not apparent in the presence of an N-methy

91 antiepileptic drugs (topiramate, lacosamide, pregabalin, levetiracetam), hypothermia, magnesium, pyri

92 Pregabalin (Lyrica(R)) is produced using a lipase based

93 The antiepileptic pregabalin (Lyrica) shows clinical promise for migraine

94 Morphine and pregabalin markedly alleviated pressure hyperalgesia, wh

95 Pregabalin may be an effective alternative.

96 r, laboratory and clinical work suggest that pregabalin may be useful in treating CIBP.

97 This study examined whether pregabalin may reduce the intensity of sciatica.

98 lds up to 74%, including the important drugs pregabalin, memantine, and the antimalarial artemisinin.

99 The effects of pregabalin on dye release are masked in the presence of

100 Finally, the action of pregabalin on dye release is most apparent before and ea

101 acebo with those of 150, 300, and 450 mg/day pregabalin on pain, sleep, fatigue, and health-related q

102 The authors examine the effects of pregabalin on presynaptic function of cultured hippocamp

103 [1-(aminomethyl)cyclohexaneacetic acid] and pregabalin (PGB) [(S)-(+)-3-isobutyl-GABA or (S)-3-(amin

104 The therapeutic drugs gabapentin and pregabalin (PGB), which are both alpha(2)delta ligands,

105 Asymmetric hydrogenation of CI-1008 (pregabalin) precursors, 39 and 40, provided good enantio

106 Pregabalin provided significantly improved treatment out

107 The study revealed that pregabalin reduces the readily releasable pool of synapt

108 Previous studies have shown that pregabalin reduces the release of neurotransmitters in s

109 Pregabalin [S-[+]-3-isobutylGABA or (S)-3-(aminomethyl)-

110 Additionally, while pregabalin significantly reduced deep dorsal horn evoked

111 As early as the week 1 observation, pregabalin significantly reduced the total Hamilton anxi

112 e CaV2.1 (P/Q-type) calcium channel subunit, pregabalin slowed the speed of SD propagation in vivo.

113 by 4.5 points, among participants receiving pregabalin than among those receiving placebo (P<0.001),

114 entation rates were significantly lower with pregabalin than with 0.5 mg of pramipexole.

115 roved or much improved was also greater with pregabalin than with placebo (71.4% vs. 46.8%, P<0.001).

116 40 or 52 weeks was significantly lower with pregabalin than with pramipexole at a dose of 0.5 mg (2.

117 the development of a new synthetic route for pregabalin that proceeds with an overall yield of 74%.

118 of suicidal ideation in the group receiving pregabalin, three in the group receiving 0.25 mg of pram

119 Furthermore, the ability of pregabalin to alleviate mechanical hypersensitivity is l

120 FM4-64 to determine details of the action of pregabalin to reduce neurotransmitter release.

121 week 6 between the 150 mg twice daily target pregabalin treatment and placebo.

122 tings of pain intensity, between each of the pregabalin treatment groups and the placebo group.

123 Our results indicate that pregabalin treatment, at concentrations that are therape

124 d no withdrawal syndrome was associated with pregabalin treatment.

125 ondary hot flash efficacy end points between pregabalin treatments and placebo.

126 ulticenter, double-blind randomized trial of pregabalin versus placebo was conducted.

127 ms, being more evident with the higher dose, pregabalin was generally well tolerated by most patients

128 Pregabalin was significantly more efficacious than place

129 In a controlled trial, the novel agent pregabalin was studied for the treatment of patients wit

130 Pregabalin was well tolerated and improved global measur

131 -mg pregabalin groups, but not by the 450-mg pregabalin (week 1, P = .06; week 4, P = .32) and the al

132 oembolic stroke patients, whereas gabapentin/pregabalin were favored in subarachnoid hemorrhage, intr

133 ocular pressure and a promising therapeutic, pregabalin, which binds to CACNA2D1 protein and lowers i

134 The interaction of gabapentin and pregabalin with conventional antiepileptic and analgesic